Chinese General Practice ›› 2023, Vol. 26 ›› Issue (29): 3650-3656.DOI: 10.12114/j.issn.1007-9572.2023.0139
• Original Research • Previous Articles Next Articles
Received:
2023-02-19
Revised:
2023-04-10
Published:
2023-10-15
Online:
2023-04-26
Contact:
LI Wenhua
通讯作者:
李文华
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0139
组别 | 例数 | 年龄(岁) | 性别(男/女) | 吸烟史〔例(%)〕 | 高血压〔例(%)〕 | 糖尿病〔例(%)〕 | 慢性肾病〔例(%)〕 | 心率(次/min) | LVEF (%) | 白细胞计数(×109/L) | 中性粒细胞计数(×109/L) | 淋巴细胞计数(×109/L) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
CI-AKI组 | 109 | 67.2±11.6 | 76/33 | 41(37.6) | 60(55.0) | 38(34.9) | 8(7.3) | 81.34±14.19 | 47.12±7.24 | 10.10±3.09 | 8.95±2.86 | 1.36±0.75 |
non-CI-AKI组 | 791 | 63.0±13.0 | 615/176 | 355(30.6) | 242(30.6) | 190(24.0) | 10(1.3) | 78.45±13.90 | 52.25±6.51 | 9.95±3.12 | 7.64±3.69 | 1.76±1.20 |
检验统计量值 | 3.151 | 3.460a | 2.052a | 0.670a | 5.954a | 18.008a | 2.030 | 7.605 | 0.462 | 3.557 | 3.307 | |
P值 | 0.002 | 0.063 | 0.152 | 0.798 | 0.015 | <0.001 | 0.043 | <0.001 | 0.644 | <0.001 | 0.001 | |
组别 | 单核细胞计数(×109/L) | CRP 〔M(P25,P75),mg/L〕 | 红细胞计数(×109/L) | 血红蛋白(g/L) | 红细胞比容(%) | 红细胞分布宽度(%) | 血小板计数(×109/L) | 血小板分布宽度(%) | 血小板平均体积(fL) | MPVLR | ||
CI-AKI组 | 0.50±0.29 | 3.20(1.40,9.80) | 4.55±0.57 | 139.00±18.27 | 42.32±5.31 | 12.81±0.91 | 202.71±58.20 | 15.02±2.16 | 11.16±1.29 | 10.68±6.01 | ||
non-CI-AKI组 | 0.52±0.33 | 3.70(1.40,14.00) | 4.64±0.57 | 142.25±17.21 | 42.86±4.96 | 12.77±1.38 | 213.96±60.34 | 14.31±2.61 | 9.98±1.23 | 8.05±5.69 | ||
检验统计量值 | 0.810 | 0.806b | 1.493 | 1.863 | 1.023 | 0.251 | 1.832 | 2.722 | 10.069 | 4.484 | ||
P值 | 0.418 | 0.534 | 0.136 | 0.063 | 0.306 | 0.802 | 0.067 | 0.007 | <0.001 | <0.001 | ||
组别 | 纤维蛋白原〔M(P25,P75),g/L〕 | ATⅢ (%) | lnNT-proBNP (pg/mL) | TG (mmol/L) | TC 〔M(P25,P75),mmol/L〕 | LDL (mmol/L) | HDL (mmol/L) | NHR | sd-LDL(mmol/L) | 空腹血糖(mmol/L) | 糖化血红蛋白(%) | 血尿素(μmol/L) |
CI-AKI组 | 2.73(2.28,3.42) | 86.96±11.75 | 7.15±1.30 | 1.57±1.41 | 4.12(3.47,4.70) | 2.62±0.96 | 0.94±0.26 | 10.07±3.69 | 0.85±0.47 | 7.08±3.02 | 6.51±1.56 | 6.41±2.21 |
non-CI-AKI组 | 2.73(2.27,3.41) | 87.54±11.84 | 6.00±1.33 | 1.28±0.62 | 4.32(3.70,4.99) | 2.76±0.88 | 1.00±0.24 | 8.08±4.79 | 0.90±0.57 | 6.79±2.82 | 6.69±1.58 | 6.09±1.98 |
检验统计量值 | 0.466b | 0.474 | 8.469 | 2.146 | 1.107b | 1.541 | 2.349 | 4.159 | 0.810 | 0.991 | 1.101 | 1.537 |
P值 | 0.982 | 0.636 | <0.001 | 0.032 | 0.172 | 0.124 | 0.019 | <0.001 | 0.418 | 0.322 | 0.271 | 0.125 |
组别 | 尿酸(μmol/L) | Scr (μmol/L) | 阿司匹林〔例(%)〕 | 氯吡格雷〔例(%)〕 | β受体阻滞剂〔例(%)〕 | ACEI/ARB 〔例(%)〕 | 他汀类药物〔例(%)〕 | CCB 〔例(%)〕 | 利尿剂〔例(%)〕 | 硝酸酯〔例(%)〕 | 低分子肝素〔例(%)〕 | |
CI-AKI组 | 320.57±131.62 | 79.79±87.07 | 109(100.0) | 109(100.0) | 98(89.9) | 61(56.0) | 107(98.2) | 14(12.8) | 76(69.7) | 59(54.1) | 80(73.4) | |
non-CI-AKI组 | 290.30±85.61 | 66.20±22.11 | 789(99.7) | 791(100.0) | 668(84.5) | 467(59.0) | 777(98.2) | 107(13.5) | 325(41.1) | 405(51.2) | 635(80.3) | |
检验统计量值 | 2.333 | 3.631 | 0.276a | 2.252a | 0.431a | 0.002a | 0.040a | 31.803a | 0.329a | 3.060a | ||
P值 | 0.020 | <0.001 | 0.599 | 0.133 | 0.512 | 0.962 | 0.841 | <0.001 | 0.566 | 0.080 |
Table 1 Comparison of clinical data of the CI-AKI and non-CI-AKI groups
组别 | 例数 | 年龄(岁) | 性别(男/女) | 吸烟史〔例(%)〕 | 高血压〔例(%)〕 | 糖尿病〔例(%)〕 | 慢性肾病〔例(%)〕 | 心率(次/min) | LVEF (%) | 白细胞计数(×109/L) | 中性粒细胞计数(×109/L) | 淋巴细胞计数(×109/L) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
CI-AKI组 | 109 | 67.2±11.6 | 76/33 | 41(37.6) | 60(55.0) | 38(34.9) | 8(7.3) | 81.34±14.19 | 47.12±7.24 | 10.10±3.09 | 8.95±2.86 | 1.36±0.75 |
non-CI-AKI组 | 791 | 63.0±13.0 | 615/176 | 355(30.6) | 242(30.6) | 190(24.0) | 10(1.3) | 78.45±13.90 | 52.25±6.51 | 9.95±3.12 | 7.64±3.69 | 1.76±1.20 |
检验统计量值 | 3.151 | 3.460a | 2.052a | 0.670a | 5.954a | 18.008a | 2.030 | 7.605 | 0.462 | 3.557 | 3.307 | |
P值 | 0.002 | 0.063 | 0.152 | 0.798 | 0.015 | <0.001 | 0.043 | <0.001 | 0.644 | <0.001 | 0.001 | |
组别 | 单核细胞计数(×109/L) | CRP 〔M(P25,P75),mg/L〕 | 红细胞计数(×109/L) | 血红蛋白(g/L) | 红细胞比容(%) | 红细胞分布宽度(%) | 血小板计数(×109/L) | 血小板分布宽度(%) | 血小板平均体积(fL) | MPVLR | ||
CI-AKI组 | 0.50±0.29 | 3.20(1.40,9.80) | 4.55±0.57 | 139.00±18.27 | 42.32±5.31 | 12.81±0.91 | 202.71±58.20 | 15.02±2.16 | 11.16±1.29 | 10.68±6.01 | ||
non-CI-AKI组 | 0.52±0.33 | 3.70(1.40,14.00) | 4.64±0.57 | 142.25±17.21 | 42.86±4.96 | 12.77±1.38 | 213.96±60.34 | 14.31±2.61 | 9.98±1.23 | 8.05±5.69 | ||
检验统计量值 | 0.810 | 0.806b | 1.493 | 1.863 | 1.023 | 0.251 | 1.832 | 2.722 | 10.069 | 4.484 | ||
P值 | 0.418 | 0.534 | 0.136 | 0.063 | 0.306 | 0.802 | 0.067 | 0.007 | <0.001 | <0.001 | ||
组别 | 纤维蛋白原〔M(P25,P75),g/L〕 | ATⅢ (%) | lnNT-proBNP (pg/mL) | TG (mmol/L) | TC 〔M(P25,P75),mmol/L〕 | LDL (mmol/L) | HDL (mmol/L) | NHR | sd-LDL(mmol/L) | 空腹血糖(mmol/L) | 糖化血红蛋白(%) | 血尿素(μmol/L) |
CI-AKI组 | 2.73(2.28,3.42) | 86.96±11.75 | 7.15±1.30 | 1.57±1.41 | 4.12(3.47,4.70) | 2.62±0.96 | 0.94±0.26 | 10.07±3.69 | 0.85±0.47 | 7.08±3.02 | 6.51±1.56 | 6.41±2.21 |
non-CI-AKI组 | 2.73(2.27,3.41) | 87.54±11.84 | 6.00±1.33 | 1.28±0.62 | 4.32(3.70,4.99) | 2.76±0.88 | 1.00±0.24 | 8.08±4.79 | 0.90±0.57 | 6.79±2.82 | 6.69±1.58 | 6.09±1.98 |
检验统计量值 | 0.466b | 0.474 | 8.469 | 2.146 | 1.107b | 1.541 | 2.349 | 4.159 | 0.810 | 0.991 | 1.101 | 1.537 |
P值 | 0.982 | 0.636 | <0.001 | 0.032 | 0.172 | 0.124 | 0.019 | <0.001 | 0.418 | 0.322 | 0.271 | 0.125 |
组别 | 尿酸(μmol/L) | Scr (μmol/L) | 阿司匹林〔例(%)〕 | 氯吡格雷〔例(%)〕 | β受体阻滞剂〔例(%)〕 | ACEI/ARB 〔例(%)〕 | 他汀类药物〔例(%)〕 | CCB 〔例(%)〕 | 利尿剂〔例(%)〕 | 硝酸酯〔例(%)〕 | 低分子肝素〔例(%)〕 | |
CI-AKI组 | 320.57±131.62 | 79.79±87.07 | 109(100.0) | 109(100.0) | 98(89.9) | 61(56.0) | 107(98.2) | 14(12.8) | 76(69.7) | 59(54.1) | 80(73.4) | |
non-CI-AKI组 | 290.30±85.61 | 66.20±22.11 | 789(99.7) | 791(100.0) | 668(84.5) | 467(59.0) | 777(98.2) | 107(13.5) | 325(41.1) | 405(51.2) | 635(80.3) | |
检验统计量值 | 2.333 | 3.631 | 0.276a | 2.252a | 0.431a | 0.002a | 0.040a | 31.803a | 0.329a | 3.060a | ||
P值 | 0.020 | <0.001 | 0.599 | 0.133 | 0.512 | 0.962 | 0.841 | <0.001 | 0.566 | 0.080 |
指标 | β | SE | Wald χ2值 | P值 | OR值 | 95%CI |
---|---|---|---|---|---|---|
LVEF | -0.102 | 0.017 | 34.866 | <0.001 | 0.903 | (0.873,0.934) |
血小板分布宽度 | 0.147 | 0.048 | 9.210 | 0.002 | 1.158 | (1.053,1.274) |
MPVLR | 0.046 | 0.015 | 9.159 | 0.002 | 1.047 | (1.016,1.079) |
NHR | 0.069 | 0.025 | 7.929 | 0.005 | 1.072 | (1.021,1.124) |
Scr | 0.006 | 0.002 | 9.153 | 0.002 | 1.006 | (1.002,1.011) |
利尿剂 | 0.842 | 0.239 | 12.390 | <0.001 | 2.321 | (1.452,3.709) |
Table 2 Multivariate Logistic regression analysis on the influencing factors for CI-AKI after PCI in AMI patients
指标 | β | SE | Wald χ2值 | P值 | OR值 | 95%CI |
---|---|---|---|---|---|---|
LVEF | -0.102 | 0.017 | 34.866 | <0.001 | 0.903 | (0.873,0.934) |
血小板分布宽度 | 0.147 | 0.048 | 9.210 | 0.002 | 1.158 | (1.053,1.274) |
MPVLR | 0.046 | 0.015 | 9.159 | 0.002 | 1.047 | (1.016,1.079) |
NHR | 0.069 | 0.025 | 7.929 | 0.005 | 1.072 | (1.021,1.124) |
Scr | 0.006 | 0.002 | 9.153 | 0.002 | 1.006 | (1.002,1.011) |
利尿剂 | 0.842 | 0.239 | 12.390 | <0.001 | 2.321 | (1.452,3.709) |
[1] |
|
[2] |
|
[3] |
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
|
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[1] | ZHANG Di, LI Hongpeng, MA Jiang, NIE Qian, SUN Jianfeng, WU Zhipeng, ZHANG Hongcai, ZHAO Jue. Effect of Ocular Acupuncture and Exercise Combination Therapy on Postoperative Heart Rate Variability and Prognosis of Patients Treated with Percutaneous Coronary Intervention [J]. Chinese General Practice, 2023, 26(36): 4535-4544. |
[2] | TANG Can, LI Xiangyang, LI Jing, QIN Haoran, ZHU Hong. The Value of Nomogram Established by Serological Indicators and Tumor Diameter to Predict the Risk of Microvascular Invasion in Hepatocellular Carcinoma [J]. Chinese General Practice, 2023, 26(36): 4514-4520. |
[3] | LIU Ruifang, XU Fangxing, LIU Tongku, ZHOU Yujie, WU Xiaofan. Evaluation of the Efficacy and Safety of "Crowbar Effect" Technique to Facilitate Balloon Crossing Resistant Chronic Total Occlusions Lesions [J]. Chinese General Practice, 2023, 26(29): 3683-3688. |
[4] | LAN Yonghao, KE Erqin, HAN Rui, MEI Yingchen, LIU Wei. Percutaneous Coronary Intervention via Distal Transradial Approach: Strengths, Weaknesses, Opportunities and Challenges [J]. Chinese General Practice, 2023, 26(27): 3355-3360. |
[5] | YUAN Mingpei, LIN Yaowang, BEI Weijie, LIU Huadong, DONG Shaohong, SUN Xin. Feasibility of Retrograde Recanalization of Occluded Radial Artery via Distal Transradial Artery Approach: a Single-center Prospective Study [J]. Chinese General Practice, 2023, 26(27): 3373-3377. |
[6] | CAI Gaojun, SHI Ganwei, LI Feng, LI Wenhua, YAN Yongmin, XUE Sheliang, XIAO Jianqiang, GU Jun, SONG Yanbin, ZHANG Liuyan, LU Wei, GONG Chun. How to Improve the Success Puncture Rate of Distal Transradial Artery Approach, "Winding Path to the Secluded": Summary of the Experience of More than 2 000 Cases [J]. Chinese General Practice, 2023, 26(27): 3361-3365. |
[7] | LIU Minghao, WANG Pan, GAO Lijian, XU Shuqing, WANG Huanhuan, ZHAO Guangxian, CHEN Jue, QIAO Shubin, XU Bo, YUAN Jinqing. Feasibility, Safety and Timing of Secondary Percutaneous Coronary Intervention via Distal Transradial Artery Approach [J]. Chinese General Practice, 2023, 26(27): 3366-3372. |
[8] | WANG Xiaowen, XIAO Tongling, WANG Yi, YANG Ying, XIA Xiaoshuang, LI Xin. Relationship between Homocysteine Level and Acute Kidney Injury in Patients with Acute Ischemic Stroke [J]. Chinese General Practice, 2023, 26(26): 3290-3296. |
[9] | LU Zuowei, CAO Hongwei, LIU Tao, ZHANG Nana, CHEN Yanyan, SHI Qinli, LIU Xiangyang, WANG Qiong, LAI Jingbo, LI Xiaomiao. Development and Validation of a Risk Prediction Model for the Progression from Microalbuminuria to Macroalbuminuria in Patients with Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2023, 26(26): 3259-3268. |
[10] | WANG Dan, WANG Jianhui, DONG Jianxiu, CHANG Wenhong, QIN Lu, LIU Qi, CHEN Chen. Effect of an Internet-based Intervention on Motor Behavior in Patients after Percutaneous Coronary Intervention [J]. Chinese General Practice, 2023, 26(21): 2603-2608. |
[11] | CHEN Yilin, LIN Ping, HAN Yongkui, WANG Yini. Research on the Construction of Adherence and Its Influencing Factors of Patients with Percutaneous Coronary Intervention in Phase Ⅰ Cardiac Rehabilitation [J]. Chinese General Practice, 2023, 26(18): 2209-2216. |
[12] | MENG Qizhe, XI Zhi, WANG Ming, WANG Yang, YANG Xiaopeng. Correlation of Blood Glucose Variability with Infarct Burden and Cognitive Impairment in Patients with Type 2 Diabetes Mellitus Complicated with Recent Small Subcortical Infarct [J]. Chinese General Practice, 2023, 26(15): 1885-1891. |
[13] | XU Di, TIAN Jinping, LIU Yunyue, XUE Leng, ZHANG Lin, SUN Guozhen, WANG Liansheng, XU Jingjing. Characteristics and Influencing Factors of Glycemic Fluctuation in Patients with Coronary Heart Disease with Type 2 Diabetes during the Peri-PCI Period [J]. Chinese General Practice, 2023, 26(15): 1863-1872. |
[14] | YAN Peng, SONG Jianling, FANG Xiangdong. Recent Developments in Parathyroid Hormone Type 1 Receptor and Kidney Disease [J]. Chinese General Practice, 2023, 26(11): 1398-1403. |
[15] | XU Wei, XU Jiyuan, LI Maoqin, LU Fei, CHENG Shuli. Predictive Value of Color Doppler Ultrasound for Acute Kidney Injury in Patients with Septic Shock [J]. Chinese General Practice, 2023, 26(09): 1104-1111. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||